Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07380412 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications
A NA study of ADHD and Sleep Disturbance, sponsored by Outliers.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT07380412: Recruiting NA study of ADHD and Sleep Disturbance, sponsored by Outliers.
NCT07380412 is a NA study of ADHD and Sleep Disturbance that is actively recruiting participants, run by Outliers. The registered enrollment target is 90 participants, below the 189-participant average among 75 other ADHD trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07380412, a NA study of ADHD and Sleep Disturbance, is actively recruiting participants, sponsored by Outliers.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a hybrid, two-arm, triple-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of the Stasis supplement on reducing oxidative stress, cortisol levels, and side effects associated with stimulant medications used for ADHD over a three-month period in adults.
Primary Outcome
Measurement of oxidative stress and cortisol levels will be assessed using the following validated biomarkers: hs-CRP and serum cortisol from blood samples 8-hydroxy-2'-deoxyguanosine (8-OHdG) from urine samples
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Stasis Daytime and Nighttime
Study Locations (1)
Nevada
- Citruslabs - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-08-12 |
| Est. Completion | 2026-03 |
| Phase | NA |
What NCT07380412 shows while recruiting
NCT07380412 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 189-participant average among 75 other ADHD trials with a reported enrollment target (52% lower).
The record links to 3 conditions, with ADHD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07380412 reports a single indexed study location in Nevada.
Frequently Asked Questions
What is clinical trial NCT07380412 about?
NCT07380412 is a clinical study titled "A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications". This is a hybrid, two-arm, triple-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of the Stasis supplement on reducing oxidative stress, cortisol levels, and side effects associated with stimulant medications used for ADHD over a three-month period in adults.
What is the current status of trial NCT07380412?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2025-08-12. Estimated completion is 2026-03.
What conditions does trial NCT07380412 study?
This clinical trial studies the following conditions: ADHD, Sleep Disturbance, Brain Fog.
What interventions are being tested in trial NCT07380412?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Stasis Daytime and Nighttime (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07380412?
This trial is sponsored by Outliers, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07380412 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07380412's enrollment target sits among peer trials
90 36th of 75 higher than 39 of 75 other ADHD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ADHD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)
RECRUITING · NA
-
Target ADHD Executive Working Memory Replication Study
RECRUITING · NA
-
Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)
RECRUITING · NA
-
Fidgeting and Attentional and Emotional Regulation in ADHD
RECRUITING · NA
-
Moms Managing Attention-Deficit/Hyperactivity Disorder (ADHD) Study
RECRUITING · NA
-
A Pilot Study of a Remote ADHD Monitoring Program
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI